A case of successful management of a hemodialysis patient with levocarnitine
-
- Higuchi Terumi
- Division of Nephrology, Keiai Hospital
-
- Hotta Sunao
- Division of Clinical Laboratory, Keiai Hospital
-
- Ishikawa Yumiko
- Dialysis Center, Keiai Hospital
-
- Yamamichi Shinya
- Dialysis Center, Keiai Hospital
-
- Kaisyo Takuto
- Dialysis Center, Keiai Hospital
-
- Nikaido Kyoko
- Dialysis Center, Keiai Hospital
-
- Setoguchi Harumi
- Dialysis Center, Keiai Hospital
-
- Yamazaki Toshio
- Division of Nephrology, Keiai Hospital
-
- Okawa Erina
- Division of Nephrology, Keiai Hospital
-
- Ando Hideyuki
- Division of Cardiology, Keiai Hospital
-
- Oikawa Osamu
- Department of Nephrology, Hypertension, and Endocrinology, and Department of Internal Medicine, Nihon University School of Medicine
-
- Kobayashi Shinichiro
- Department of Nephrology, Hypertension, and Endocrinology, and Department of Internal Medicine, Nihon University School of Medicine
-
- Abe Masanori
- Department of Nephrology, Hypertension, and Endocrinology, and Department of Internal Medicine, Nihon University School of Medicine
-
- Okada Kazuyoshi
- Department of Nephrology, Hypertension, and Endocrinology, and Department of Internal Medicine, Nihon University School of Medicine
Bibliographic Information
- Other Title
-
- レボカルニチンが著効した血液透析患者の1例
- 症例報告 レボカルニチンが著効した血液透析患者の1例
- ショウレイ ホウコク レボカルニチン ガ チョコウシタ ケツエキ トウセキ カンジャ ノ 1レイ
Search this article
Abstract
We present a case of a patient with end-stage renal disease maintained on hemodialysis, who was managed successfully by oral levocarnitine treatment. The patient was a 58-year-old male who was started on hemodialysis for end-stage renal disease secondary to diabetic nephropathy in April 2008. Echocardiography revealed systolic and diastolic dysfunction with EF of 48.9% and E/e’ of 19.5 and severe left ventricular hypertrophy (LMVI 151 g/m2). rHuEPO was administered subcutaneously at 9,000 IU/week. Because the ESA resistance index (ERI), calculated as the weekly weight-adjusted dose of EPO divided by the hemoglobin level (rHuEPO doses/kg/g/dL/week), was relatively high (13.5), oral levocarnitine therapy (1,200 mg/day) was started. At 1 year of therapy, echocardiographic parameters improved with EF of 72.7% and LVMI of 107 g/m2. NT-proBNP decreased from 12,800 pg/mL to 7,850 pg/mL. The dose of rHuEPO could be reduced from 9,000 U/week to 3,000 U/week and ERI decreased markedly from 13.5 to 3.9. Brachial-ankle pulse wave velocity (baPWV) as an arteriosclerotic indicator decreased from 1,832 cm/sec to 1,545 cm/sec. Arm muscle area (AMA) increased from 32.9 cm2 to 39.3 cm2. ALT and AST decreased slightly from 12 U/L to 9 U/L and from 14/U to 9 U/L, respectively.
Journal
-
- Nihon Toseki Igakkai Zasshi
-
Nihon Toseki Igakkai Zasshi 48 (8), 477-482, 2015
The Japanese Society for Dialysis Therapy
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204678173312
-
- NII Article ID
- 130005095172
-
- NII Book ID
- AN10432053
-
- ISSN
- 1883082X
- 13403451
-
- NDL BIB ID
- 026725675
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed